Trial reportJournal of clinical oncology : official journal of the American Society of Clinical Oncology2021
Treatment of Pediatric Adrenocortical Carcinoma With Surgery, Retroperitoneal Lymph Node Dissection, and Chemotherapy: The Children's Oncology Group ARAR0332 Protocol.
Trial report in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
53 citing papers in PubMed, 1 synthesis or guideline pooled it, 85 citations in OpenAlex.
- Efficacy and Safety of Radiotherapy and Systemic Treatments in Adrenocortical Carcinoma: Systematic Review and Meta-Analysis.The Journal of clinical endocrinology and metabolism · 2025Pooled it
- CpG hypermethylation and WNT/AP-1 cooperativity define the epigenetic landscape and a clinical subgroup of high-risk pediatric adrenocortical carcinoma.Nature communications · 2026Article
- ENPP3 CAR T cells combined with CD206 modulation suppress adrenocortical carcinoma.Journal for immunotherapy of cancer · 2026Article
- Review
- A Rare Paediatric Adrenocortical Carcinoma with Aggressive Clinical Course.Journal of the ASEAN Federation of Endocrine Societies · 2026Article
- Surgical Management and Outcomes in Pediatric Adrenocortical Carcinoma: A Pediatric Surgical Oncology Research Collaborative Study.Annals of surgical oncology · 2026Article
- Histopathological and Molecular Characteristics of Pediatric Adrenocortical Tumors: where Do we Stand?Endocrine pathology · 2026Review
- Factors Associated With Rare Pediatric Cancer Trial Enrollment: A Report From the Children's Oncology Group Rare Tumors Committee.Pediatric blood & cancer · 2026Article
- Interpretable Machine Learning Model for Survival Prediction in Pediatric Adrenocortical Tumors.Journal of the Endocrine Society · 2026Article
- Three cases of pediatric adrenocortical carcinoma with intermediate malignant potential: a case report with literature review.AME case reports · 2026Article
- Case Report: Androgen-secreting pediatric adrenocortical tumor of uncertain malignant potential presenting with virilization in a 19-month-old girl.Frontiers in endocrinology · 2026Article
- Mitotane dosage, plasma levels, and anthropometric measurements in pediatric adrenocortical carcinoma.Endocrine oncology (Bristol, England) · 2026Article
- Functional and behavioral outcomes in pediatric adrenal carcinoma under mitotane therapy: a caregiver-reported pilot study.Endocrine oncology (Bristol, England) · 2026Article
- Rare but not forgotten: Therapeutic advancements for rare childhood cancers.Molecular therapy. Oncology · 2025Review
- Epidemiological trends of adrenalectomies in Brazil: A cohort-based study of the Brazilian public health system.Archives of endocrinology and metabolism · 2025Article
- Mitotane-Induced Endocrine Alterations in Children with Adrenocortical Carcinoma: Clinical Implications from a 20-Year Retrospective Study.Children (Basel, Switzerland) · 2025Article
- Identification and validation of susceptibility modules and hub genes of adrenocortical carcinoma through WGCNA and machine learning.Discover oncology · 2025Article
- Inflammation-based score in pediatric adrenocortical carcinoma.Endocrine-related cancer · 2025Article
- Spanish consensus on the diagnosis and management of adrenocortical carcinoma.Endocrine-related cancer · 2025Review
- Pediatric adrenocortical carcinoma complicated by uric acid nephrolithiasis: a unique case report.BMC urology · 2025Article
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
Authors and funding
18 authors at 11 institutions in 3 countries.
Funding
Abstract
purposeAdrenocortical carcinoma (ACC) is a rare aggressive pediatric malignancy with distinct biology. Its treatment follows the principles developed for adults; pediatric-specific studies are scarce. PATIENTS AND
methodsProspective single-arm risk-stratified interventional study. Study objectives were (1) to describe the outcome of patients with stage I ACC treated with adrenalectomy alone; (2) to describe the outcome of stage II patients (completely resected > 200 cc or > 100 g) treated with adrenalectomy and retroperitoneal lymph node dissection; and (3) to describe the outcome of patients with stage III or IV treated with mitotane and chemotherapy.
resultsBetween September 2006 and May 2013, 78 patients (77 eligible, 51 females) were enrolled. The 5-year event-free survival estimates for stages I (24 patients), II (15 patients), III (24 patients), and IV (14 patients) were 86.2%, 53.3%, 81%, and 7.1%, respectively. The corresponding 5-year overall survival estimates were 95.2%, 78.8%, 94.7%, and 15.6%, respectively. On univariate analysis, age, stage, presence of virilization, Cushing syndrome, or hypertension, germline
conclusionOutcome for children with stage I ACC is excellent with surgery. Outcome for patients with stage II disease is inferior despite retroperitoneal lymph node dissection. Patients with stage III ACC have an excellent outcome combining surgery and chemotherapy. Patients with stage IV ACC are older and have a poor outcome; new treatments should be explored for this high-risk group. The combination of mitotane and chemotherapy as prescribed in ARAR0332 resulted in significant toxicity; one third of patients with advanced disease could not complete the scheduled treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.